08:21 ETCORE Biomedicine Signs Exclusive Licensing Agreement with Eisai for Precision Oncology Programsprnewswire·12 hours ago4523
Pfizer and Eisai Commence Co-promotion of "NURTEC(R)" for the Acute Treatment and Prophylaxis (Preventive Treatment) of MigraineJapan Corporate News·1 day ago, 01:50 PMPFE+2.35%4523
AWS Announces General Availability of AWS HealthOmics in the Asia Pacific (Tokyo) RegionPress Releases·1 day ago, 10:54 AMAMZN-0.23%AMZG-0.41%
Weekly Recap: LEQEMBI IQLIK FDA approval and lecanemab SC bioequivalenceTradingView·Jul 20 at 05:14 PM4523
Does Real‑World Leqembi Iqlik Data And At‑Home Use Shift The Bull Case For Eisai (TSE:4523)?Simplywall·Jul 20 at 04:13 PM4523
Marketing Authorization Application for In-house Developed Insomnia Drug Lemborexant Accepted for Evaluation by European Medicines Agency (EMA)Japan Corporate News·Jul 17 at 06:16 PM4523
LEQEMBI(R) Real-World LEADER Study Presented at AAIC(R) 2026 Finds Over 75% of Early Alzheimer's Patients Enrolled in the Study Remained Stable and Nearly 7% Improved Over an Average of 17 Months of TreatmentJapan Corporate News·Jul 15 at 01:50 PM4523BIIB+2.73%
FDA Approves LEQEMBI IQLIK(R) (lecanemab-irmb) Subcutaneous Injection as an Initiation Dose for Early Alzheimer's DiseaseJapan Corporate News·Jul 15 at 12:28 PM4523BIIB+2.73%
Eisai Presents Latest Findings Showed Etalanetug Reduced Alzheimer's Disease Tau Tangle-Specific Plasma Biomarker MTBR-tau243 at Alzheimer's Association International Conference(R) (AAIC(R)) 2026Japan Corporate News·Jul 15 at 12:01 PM4523
More than 75% of Leqembi®-treated patients remained stable and nearly 7% improved over an average of 17 months of treatment in real-world LEADER study data presented at AAIC® 2026 | B Stock NewsStockTitan·Jul 14 at 02:39 AM4523
